Related Experiment Video
Updated: Sep 20, 2025
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.8K
α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical
Yaoyun Kuang1, Hengxu Mao1, Xiaoyun Huang2
1Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Translational Neurodegeneration
|November 22, 2024
Summary
Seed amplification assays (SAA) detect alpha-synuclein (αSyn) misfolding for early diagnosis of synucleinopathies like Parkinson's disease. This method enables molecular diagnosis before symptoms appear, improving treatment timing.
Area of Science:
- Neurodegenerative diseases
- Molecular diagnostics
- Biomarker detection
Background:
- Synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), are defined by alpha-synuclein (αSyn) pathology.
- Current diagnostics rely on late-manifesting motor symptoms, delaying treatment initiation.
- Symptomatic overlap between PD and MSA necessitates precise differential diagnostic tools.
Purpose of the Study:
- To review the application of seed amplification assay (SAA) technology for diagnosing synucleinopathies.
- To explore the potential of SAA for early, molecular diagnosis of αSyn misfolding.
- To discuss challenges and future directions for SAA in clinical settings.
Main Methods:
- Review of recent research on seed amplification assays (SAAs).
- Focus on detecting pathological alpha-synuclein (αSyn) in biological samples.
- Analysis of SAA's effectiveness and reproducibility in diagnosing synucleinopathies.
Main Results:
- SAA can detect αSyn misfolding even at preclinical stages of synucleinopathies.
- SAAs offer a tool for early molecular diagnosis, preceding clinical symptom onset.
- Research validates SAA's effectiveness and reproducibility for synucleinopathy diagnosis.
Conclusions:
- SAA technology holds significant promise for the early and differential diagnosis of synucleinopathies.
- Optimizing SAA for accessible samples and specific αSyn species is crucial for clinical translation.
- Further development is needed to fully integrate SAA into routine clinical practice for neurodegenerative diseases.
